HPV Associated Disorders Treatment Market size is estimated at USD 20.7 billion in 2024 and is expected to reach USD 35.5 billion by the end of 2037, witnessing around 4.6% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of the HPV associated disorders treatment is assessed at USD 45.1 billion.
The HPV associated disorders treatment market is experiencing robust growth, driven by the rising prevalence of HPV-associated disorders, including cervical, anal, and oropharyngeal cancers, globally. Diagnostic advancements such as NGS and molecular testing, along with the development of targeted therapies and vaccines are expanding treatment options. For instance, in June 2020, Merck received the U.S. FDA approval for GARDASIL 9, for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. Furthermore, government initiatives promoting HPV vaccination and screening programs, especially in developed regions, are further fueling the HPV associated disorders treatment market growth.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.6% |
|
Base Year Market Size (2024) |
USD 20.7 billion |
|
Forecast Year Market Size (2037) |
USD 35.5 billion |
|
Regional Scope |
|
Treatment Type (Medication, Surgery)
Medication is projected to dominate the treatment type segment during the forecast period. Primary drivers for the segment’s growth include the increased availability of antiviral and immunomodulatory drugs. These drugs target HPV-related infections and complications including genital warts and cervical dysplasia. The rising incidence of HPV-associated cancers such as cervical, anal, and oropharyngeal cancers, has also boosted the demand for therapeutic medicines. Moreover, drug formulation advances, including topical creams, oral medications, and injectables, have made treatments more effective and accessible to patients.
The shift towards non-invasive options, compared to more aggressive treatments such as surgery, has further enhanced the adoption of medication as the preferred treatment method. Ongoing research and clinical trials in HPV vaccines and therapeutic drugs are expected to boost the segment’s growth. For instance, in March 2024, Bayer AG and Thermo Fisher Scientific Inc. announced a collaboration to develop NGS-based CDx, for cancer medicines. The collaboration focuses on creating advanced diagnostics that enable more precise and personalized medicinal treatments for patients with HPV-related cancers. As newer medications enter the market, the segment’s growth is anticipated to reach greater heights.
End use (Hospitals, Ambulatory Surgical Centers)
Hospitals segment is set to account for around 45.1% HPV associated disorders treatment market share by 2037. The availability of advanced medical infrastructure in hospitals allows complex treatment administration such as surgical procedures, radiation therapy, and advanced medications for HPV-related conditions. Furthermore, hospitals are also equipped with multidisciplinary teams of specialists, providing comprehensive care for HPV- associated disorders. Hospitals also have access to the latest diagnostic tools, including next-generation sequencing, and molecular diagnostics, which are crucial for early detection of diseases.
Government support and insurance coverage for hospital-based treatments also play a key role in strengthening their position in the HPV treatment landscape. For instance, as stated in a report by the American Hospital Association, approximately 90 percent of U.S. residents have health insurance with significant gains in health coverage occurring over the past five years. The Pradhan Mantri Jan Arogya Yojana (PM-JAY) is a flagship scheme of the Government of India. The health assurance scheme aims at providing a health cover of Rs. 5 lakhs per family per year for secondary and tertiary care hospitalization to over 12 crores of poor and vulnerable families that form the bottom 40% of the Indian population. Such factors are projected to further boost the segment’s growth in the forthcoming years.
Our in-depth analysis of the HPV associated disorders treatment market includes the following segments
|
Disease Type |
|
|
Treatment Type |
|
|
End use |
|
North America Market Analysis
North America HPV associated disorders treatment market is projected to register the highest share of 47% during the forecast period. Growing public health initiatives, particularly the widespread implementation of HPV vaccination programs, have played a critical role in shaping this market. The Centers for Disease Control and Prevention (CDC) has been pivotal in promoting vaccination, which has led to a decrease in the incidence of HPV-related diseases. For instance, the American Cancer Society launched a mission HPV Cancer Free, which is a public health initiative to eliminate vaccine-preventable HPV cancers as a public health problem. The initiative aims to reach an annual vaccination rate of 80% of 13-year-olds in the United States by 2026. Such initiatives are boosting the HPV associated disorders treatment market growth in the region significantly.
The U.S. HPV associated disorders treatment market is increasingly being driven by widespread awareness of HPV’s health impacts, high vaccination rates, and advancements in diagnostic technologies. In November 2018, the President’s Cancer Panel published an article stating that about 79 million people were already infected with HPV, and about 14 million would further become infected with HPV each year, in the U.S. As per an article published by the CDC, in July 2024, it is recommended to start routine vaccines for children 11 or 12 years old to protect against HPV infections that can cause some cancers later in life. These factors are further driving the market growth of the country.
Canada market is fueled by comprehensive public health strategies and increasing awareness of HPV-related diseases. As per the HPV Information Center, March 2023, concluded that current estimates indicate that every year 1422 women are diagnosed with cervical cancer, and 637 die from the disease in the country. Public health campaigns, combined with educational efforts regarding the importance of HPV vaccination and regular screenings, have contributed to the diseases’ greater understanding. These ongoing efforts are further projected to boost the country’s market growth during the forecast period.
APAC Market Statistics
Improved healthcare infrastructure, in addition to increasing awareness and government initiatives, is significantly driving the market growth in the APAC. The rising number of cancer caser cases, along with genital warts, and recurrent respiratory papillomatosis (RRP) cases, are contributing to the region’s market growth. As per the World Economic Forum, October 2023, Asia accounted for 58% of cervical cancer deaths worldwide. Where the number of cases a rising in countries such as India, and China, countries like Japan, South Korea, and Australia are leading in vaccine coverage and screening programs. WHO’s global strategy of November 2020 aiming to eliminate cervical cancer as a public health problem by 2030, is also boosting the market growth in the Asia Pacific.
India is expanding rapidly, primarily driven by the rising incidence of cervical cancers among adolescent girls. Additionally, increased awareness campaigns focusing on HPV’s role in anal and oropharyngeal cancers, such as the Federation of Obstetric and Gynecological Societies of India (FOGSI) are promoting a broader understanding of HPV-related health issues. These factors are predicted to enhance the overall market growth in the country.
China is witnessing considerable growth with significant investments in healthcare infrastructure. The government is actively promoting screening initiatives to detect precancerous lesions early, contributing to the overall market growth. In May 2024, the Bill & Melinda Gates Foundation of China in partnership with the Chinese Academy of Medical Sciences Cancer Hospital and the Ordos Health Commission started a free HPV vaccine pilot program in the country. Initiatives such as this are also boosting the market growth in the country.
Companies dominating this market are adopting a wide number of strategies for market expansion and to gain a competitive edge. Few companies such as Merck and GlaxoSmithKline leverage the market with extensive marketing and education campaigns for their vaccines. Similarly, companies also adopt strategies such as partnerships for R&D, mergers, acquisitions, and launches. For instance, in December 2022, Moderna, Inc. and Merck announced the successful trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA. Additionally, emerging biotech firms are exploring personalized medicine approaches, emphasizing tailored therapies, and diversifying treatment options, and driving HPV associated disorders treatment market growth. Some of the key market players include:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?